Why a $20.7B Missile Deal Exposes a Western Munitions Crisis

The $20.7 Billion Signal

The Pentagon’s latest contract looks like a win for American defense manufacturing. Raytheon, now part of RTX, will receive $20.7 billion for AMRAAM medium-range air-to-air missiles under a provisional multi-year agreement. The stated goal is simple: refill stockpiles drained by simultaneous conflicts in Ukraine and the Middle East.

But read the fine print and another story emerges. RTX says it nearly doubled AMRAAM production in 2025 compared to the prior year. Even so, the Pentagon is committing billions in advance — and Congress still hasn’t fully funded the multi-year package. That gap between announcement and appropriation tells you everything about where Western munitions capacity actually stands.

This is not a company scaling production comfortably. This is a company being bailed out of a production crisis by a buyer desperate for certainty.

What the Numbers Actually Mean

RTX set an annual production target of at least 1,900 AMRAAMs this year — a figure framed as ambitious under the Pentagon’s “Arsenal of Freedom” initiative. Nearly doubling output from a low base doesn’t mean the line is running hot. It means it was barely limping before.

The parallel contract awarded to Lockheed Martin in July tells the same story in larger numbers. $58.6 billion for Patriot interceptor missiles across seven fiscal years through 2032. Executive commentary from both companies flags the same risk: without confirmed congressional funding, investment in parts and facilities remains hostage to political timelines.

The pattern is unmistakable. The US defense industrial base is responding to a shock — two active theaters consuming munitions at rates that dwarf peacetime assumptions — by throwing money at suppliers who were never built for this pace.

The Alliance Squeeze

Here is what English-language coverage of this deal tends to miss: the collateral damage to allies already racing to build their own missile production lines.

AMRAAMs are not just fighter aircraft weapons. They form the core of the NASAMS (National Advanced Surface-to-Air Missile System), a mobile short-range air defense platform deployed by Ukraine, Qatar, Oman, and a dozen other nations. The Pentagon’s priority will be restocking American inventory first. Every AMRAAM directed toward US stockpiles is one less unit available for allied export — or for the very systems Korea and Japan depend on for their own air defense architectures.

South Korea is no longer content to import. Hanwha and LIG Nex1 are investing heavily in domestic interceptor and strike-missile production. Hanwha’s aerospace division has publicly targeted significant output expansion through the latter half of this decade. LIG Nex1 is pursuing similar ambitions in guided munitions. Both companies are betting that geographic proximity and alliance partnership will give them a foothold in a market that can no longer rely on American surplus.

Japan faces equivalent pressure. Its domestic defense industry — led by Mitsubishi Heavy Industries and Kawasaki Heavy Industries — is under explicit government direction to expand missile production capacity. The Aegis Ashore replacement programs, land-based interceptor deployments, and strike capability expansion all require missiles that the US cannot casually spare.

The Real Question Is Timing

The structural problem is not that the US lacks the will to produce more weapons. It is that building production capacity takes years, and the window for allied self-reliance is narrowing faster than the American supply chain can widen.

RTX’s near-doubling of AMRAAM output sounds dramatic until you consider what it implies about the starting position. If production was roughly 1,000 units annually and has now climbed toward 1,900, the base was dangerously thin. The Pentagon itself acknowledged the depletion concern. Congressional funding remains uncertain. Factory walls do not go up on multi-year contract promises alone.

For Seoul and Tokyo, the implication is stark. Waiting for American deliveries means waiting through a bottleneck that benefits Washington first. Building domestic lines means investing billions in capacity that may not hit meaningful output until the very moment alliance demand peaks.

Neither option is comfortable. But the alternative — hoping the munitions crisis resolves itself — is not a strategy anyone in the Indo-Pacific can afford.

Who Wins, Who Loses

RTX wins in the short term. The contract provides revenue visibility and a mandate to expand. American voters and lawmakers see a company ramping production. Shareholders get a narrative of industrial renewal replacing the prior focus on buybacks.

The US defense industrial base wins a breathing room it does not yet know how to use efficiently. Multi-year contracts create planning stability. But stability without confirmed funding is just a promise with a price tag.

Allied defense planners lose. Every announcement of American production increases followed by funding uncertainty reinforces the same calculation: self-reliance is no longer optional. Hanwha, LIG Nex1, Mitsubishi, and Kawasaki now have political cover and strategic urgency to move faster. The question is whether their timelines align with the threat environment.

Consumers of Western munitions — Ukraine included — face the hardest calculus. The US is sending more missiles to Ukraine. It is also reserving优先 allocation for its own forces. The margin between those priorities is where alliance friction lives.

What Comes Next

Watch three things over the next twelve months. First, whether Congress funds the full multi-year value of both the Raytheon and Lockheed contracts — not the projected total, but the actual appropriation. Second, whether RTX and Lockheed Martin can convert contract promises into verified output increases, not just press releases about targets. Third, and most consequential for the rest of the world: whether Seoul and Tokyo accelerate indigenous programs fast enough to reduce dependency on a supply chain that is already overcommitted.

The $20.7 billion missile contract is not a solution to the Western munitions shortage. It is a diagnosis. The treatment — building durable production capacity across multiple allied industrial bases — has not yet begun.